Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Alcon(ALC) Businesswire·2024-01-10 05:30Alcon(ALC) Businesswire·2024-01-10 05:30
R1Alcon(ALC) Businesswire·2024-01-10 05:30 R1Alcon(ALC) Businesswire·2024-01-10 05:30